Repeat aortic valve surgery: contemporary outcomes and risk stratification

Autor: Thierry Bové, Laurent De Backer, Yves Van Belleghem, Katrien François, Tine Philipsen, Thomas Martens
Rok vydání: 2020
Předmět:
Male
Reoperation
Pulmonary and Respiratory Medicine
Aortic valve
medicine.medical_specialty
medicine.medical_treatment
030204 cardiovascular system & hematology
Risk Assessment
Cohort Studies
03 medical and health sciences
Aortic aneurysm
Postoperative Complications
0302 clinical medicine
Aortic valve repair
Valve replacement
Aortic valve replacement
Risk Factors
Interquartile range
Internal medicine
Odds Ratio
medicine
Humans
Aorta
Aged
Proportional Hazards Models
Retrospective Studies
Heart Valve Prosthesis Implantation
Adult Cardiac
Endocarditis
business.industry
Hazard ratio
Aortic Valve Stenosis
Odds ratio
Middle Aged
medicine.disease
Aortic Aneurysm
Treatment Outcome
medicine.anatomical_structure
030228 respiratory system
Aortic Valve
Heart Valve Prosthesis
Cardiology
Female
Surgery
Cardiology and Cardiovascular Medicine
business
Zdroj: Interact Cardiovasc Thorac Surg
ISSN: 1569-9285
DOI: 10.1093/icvts/ivaa257
Popis: OBJECTIVES Redo aortic valve surgery (rAVS) is performed with increasing frequency, but operative mortality is usually higher compared to that associated with primary aortic valve surgery. We analysed our patients who had rAVS to determine the current outcomes of rAVS as a surgical benchmark in view of the growing interest in transcatheter valve techniques. METHODS We retrospectively reviewed 148 consecutive patients [median age 67.7 years (interquartile range 54.9–77.6); 68.2% men] who underwent rAVS following aortic valve replacement (81.6%), aortic root replacement (15%) or aortic valve repair (3.4%) between 2000 and 2018. RESULTS Indications for rAVS were structural valve dysfunction (42.7%), endocarditis (37.8%), non-structural valve dysfunction (17.7%) and aortic aneurysm (2.1%). Valve replacement was performed in 69.7%, and 34 new root procedures were necessary in 23%. Early mortality was 9.5% (n = 14). Female gender [odds ratio (OR) 6.16], coronary disease (OR 4.26) and lower creatinine clearance (OR 0.95) were independent predictors of early mortality. Follow-up was 98.6% complete [median 5.9 (interquartile range 1.7–10.9) years]. Survival was 74.1 ± 3.7%, 57.9 ± 5.1% and 43.8 ± 6.1% at 5, 10 and 14 years, respectively. Cox regression analysis revealed female gender [hazard ratio (HR) 1.73], diabetes (HR 1.73), coronary disease (HR 1.62) and peripheral vascular disease (HR 1.98) as independent determinants of late survival. CONCLUSIONS Despite many urgent situations and advanced New York Heart Association functional class at presentation, rAVS could be performed with acceptable early and late outcomes. Risk factors for survival were female gender, coronary disease and urgency. In this all-comers patient cohort needing rAVS, only a minority would eventually qualify for transcatheter valve-in-valve procedures.
Databáze: OpenAIRE